Translarna™ (ataluren)* has been approved in the European Union for ambulatory patients aged 2 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene.

Translarna Summary of Product Characteristics

Learn more at

*Translarna is an investigational new drug in the US



EMFLAZA® (deflazacort) is approved in the US for the treatment of Duchenne muscular dystrophy in patients 5 years of age and older.

Please see the accompanying full Prescribing Information

Click here for Important Safety Information

Learn more at

For medical information, product complaints, or to report an adverse event, please call 1‑866‑562‑4620.

You may report adverse events to FDA at 1‑800‑FDA‑1088 or




PTC has gained the commercialization rights for TEGSEDI™ (inotersen) in Latin America. Akcea will commercialize TEGSEDI™ (inotersen) outside of Latin American. TEGSEDI™ (inotersen) is approved in the United States, Canada and the European Union for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults.

By selecting Confirm, you are leaving the PTC Therapeutics U.S. website. This external link is provided for your convenience. Please note that external links or web sites may not be controlled by PTC Therapeutics, and thus not subject to our Privacy policy and Terms of use.

Thank you for visiting our site.
Cancel Confirm
This site uses cookies to store information on your computer.
Cancel Continue